4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $57,018 | -35.9% | 4,479 | -9.0% | 0.04% | -34.0% |
| Q2 2023 | $88,959 | +25.0% | 4,923 | +18.9% | 0.05% | +35.9% |
| Q1 2023 | $71,167 | -44.1% | 4,140 | -27.8% | 0.04% | -40.9% |
| Q4 2022 | $127,286 | +9.7% | 5,731 | -25.4% | 0.07% | +26.9% |
| Q1 2022 | $116,000 | -35.2% | 7,683 | -5.6% | 0.05% | -23.5% |
| Q4 2021 | $179,000 | -8.7% | 8,140 | +12.2% | 0.07% | -20.9% |
| Q3 2021 | $196,000 | +6.5% | 7,257 | -5.0% | 0.09% | +13.2% |
| Q2 2021 | $184,000 | – | 7,642 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |